Profit Decline Due to Increased Expenses Such as Research and Development Costs
First written in FY2017-Q3. 7 of 18 entries say "Mitigated", first in FY2018-Q3. Latest entry: FY2026.
1 other company's latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「As a result of these activities, research and development costs for the consolidated fiscal year were ¥3,709 million, down 9.7% year on year.」
Research and development costs decreased from ¥4,106 million in the previous fiscal year to ¥3,709 million, while full-year operating profit increased 1.4% year on year. - FY2026-H1Lower operating profit due to costs and core-system investmentAnnual report
「Operating profit was ¥3,641 million, down 43.6% from the same interim period of the previous year, due to lower sales and higher expenses, including costs and investment in core systems at overseas subsidiaries.」
In addition to lower sales, higher expenses for costs and investment in core systems at overseas subsidiaries became factors behind the decline in operating profit. - FY2025Increase in R&D expensesAnnual report
「As a result of these activities, research and development costs for the consolidated fiscal year increased from the previous year's actual results to ¥4,106 million, up 10.2% year on year.」
Research and development costs increased from ¥3,726 million in the previous fiscal year to ¥4,106 million. - FY2025-H1Increase in R&D expensesAnnual report
「The Group's research and development activities amounted to ¥1,943 million for the six-month consolidated period.」
Research and development costs for the interim period were ¥1,943 million, up from ¥1,746 million in the same interim period of the previous year. - FY2024Increase in R&D expensesAnnual report
「As a result of these activities, research and development costs for the consolidated fiscal year increased from the previous year's actual results to ¥3,726 million, up 7.8% year on year.」
Research and development costs increased from ¥3,456 million in the previous fiscal year to ¥3,726 million. - FY2024-Q2UK regulatory review and specific increases in expensesAnnual report
「Meanwhile, operating profit was ¥5,327 million, down 9.6% year on year, due to higher expenses resulting from a partial review of the UK pharmaceutical pricing regulatory system, as well as increases in promotional expenses and depreciation.」
In addition to the previously identified factors behind higher expenses, the partial review of the UK pharmaceutical pricing regulatory system was specifically identified as a factor behind the decline in operating profit. - FY2024-Q1Lower operating profit due to higher expensesAnnual report
「Meanwhile, operating profit was ¥2,970 million, down 0.2% year on year, due to increases in expenses including promotional expenses, research and development costs and depreciation.」
Unlike the more efficient use of expenses identified as a factor behind improved profit through the previous fiscal year, increases in promotional expenses, research and development costs and depreciation became factors behind the decline in operating profit in the current quarter. - FY2023MitigatedAnnual report
「As a result of these activities, research and development costs for the consolidated fiscal year decreased from the previous year's actual results to ¥3,456 million, down 27.8% year on year.」
Research and development costs, which had previously pressured profit, decreased 27.8% year on year, while full-year operating profit increased 41.6%. - FY2020-Q3MitigatedAnnual report
「Profit was supported by efforts to use research and development costs efficiently, with operating profit reaching ¥3,382 million, up 10.5% year on year.」
This represents a change from periods when higher expenses, including research and development costs, pressured profit. For the nine months ended the third quarter, efficient use of research and development costs was identified as a factor behind higher operating profit. - FY2019MitigatedAnnual report
「This was attributable in part to a decrease in retirement benefit expenses from ¥573 million in the previous consolidated fiscal year to negative ¥109 million, and a decrease in research and development costs from ¥7,331 million to ¥6,832 million.」
Expenses, including research and development costs, decreased from the previous fiscal year and became a factor behind lower selling, general and administrative expenses. - FY2019-Q2MitigatedAnnual report
「Research and development costs」
Research and development costs decreased from ¥3,908 million in the same period of the previous year to ¥2,883 million. The previous factor of profit pressure arising from higher research and development costs was not identified in the same form for the six months ended the second quarter. - FY2019-Q1Higher profit due to the timing of research and development expense recognitionAnnual report
「In addition to solid overseas performance, the Company worked to use expenses efficiently, and some research and development costs were deferred until after the second quarter.」
This represents a change from periods when higher expenses, including research and development costs, pressured profit. In the current quarter, more efficient use of expenses and the deferral of research and development expense recognition were identified as factors behind higher profit. - FY2018MitigatedAnnual report
「This was attributable in part to a decrease in research and development costs from ¥8,458 million in the previous consolidated fiscal year to ¥7,331 million.」
Research and development costs decreased from ¥8,458 million to ¥7,331 million, contributing to lower selling, general and administrative expenses and higher operating profit. - FY2018-Q3MitigatedAnnual report
「Meanwhile, supported by solid overseas performance and contributions from lower selling, general and administrative expenses, operating profit was ¥4,587 million, up 26.0% year on year.」
Unlike in the past, when higher expenses were identified as a factor behind declining profit, the Company stated that lower selling, general and administrative expenses and other factors contributed to higher profit in the current quarter. - FY2018-Q2Continued impact of higher research and development costsAnnual report
「Meanwhile, profit was affected in part by an increase in expenses, including research and development costs. Operating profit was ¥2,393 million, down 24.0% year on year, and ordinary profit was ¥2,534 million, down 17.8%.」
The increase in expenses, including research and development costs, continued to be identified as a factor behind the decline in operating profit and ordinary profit for the six months ended the second quarter. - FY2018-Q1Z-215 development termination costs incurredAnnual report
「In addition to the gradual decline in revenue, the Company discontinued all ongoing research and development following the termination of its licensing agreement with EA Pharma Co., Ltd. for a new proton pump inhibitor, hereinafter referred to as “Z-215,” and recognized the associated termination costs as research and development expenses in the first quarter. Operating profit was ¥597 million, down 65.3% year on year.」
In addition to the increase in expenses, including research and development costs, termination costs associated with discontinuing development of Z-215 became a specific factor behind the decline in profit in the current quarter. - FY2017Shift in factors behind the decline in profitAnnual report
「Research and development costs decreased from ¥8,579 million in the previous consolidated fiscal year to ¥8,458 million, while promotional expenses, depreciation and other costs increased.」
The focus of the factors behind the decline in profit shifted for the full year from the increase in expenses, including research and development costs, identified in the previous quarterly report to increases in promotional expenses, depreciation and other costs. - FY2017-Q3First statedAnnual report
「Meanwhile, profit was affected by a substantial increase in expenses, including research and development costs. Operating profit was ¥3,641 million, down 4.0% year on year; ordinary profit was ¥3,502 million, down 7.0%; and net profit attributable to owners of the parent was ¥2,873 million, down 13.8%.」
The increase in expenses, including research and development costs, was explicitly identified for the first time as a factor behind the year-on-year declines in operating profit, ordinary profit and net profit attributable to owners of the parent.